• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by C4 Therapeutics Inc.

    2/12/26 5:02:01 PM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CCCC alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)


    C4 Therapeutics, Inc

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)


    12529R107

    (CUSIP Number)


    12/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    12529R107


    1Names of Reporting Persons

    Soleus Private Equity Fund III, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    6,072,822.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    6,072,822.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,072,822.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.9 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  (1) The shares reported in the table above are held directly by Soleus Private Equity Fund III, L.P. ("Soleus PE"). Soleus Private Equity GP III, LLC ("Soleus PE GP") is the sole general partner of Soleus PE, Soleus PE GP III, LLC is the sole manager of Soleus PE GP, Soleus Capital Management, L.P. ("SCM") is the investment manager for Soleus PE and for Soleus Capital Master Fund, L.P. ("Master Fund"), and Soleus GP, LLC is the sole general partner of SCM. Guy Levy is the sole managing member of each of Soleus PE GP III, LLC and of Soleus GP, LLC. Each of Mr. Levy, Soleus PE GP III, LLC, Soleus PE GP, SCM and Soleus GP, LLC disclaims beneficial ownership of these shares held by Soleus PE other than for the purpose of determining their obligations under Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose. (2) The number of shares reported in the table above includes warrants to purchase up to 5,822,829 shares of the common stock of C4 Therapeutics, Inc. (the "Issuer"). (3) The percentage set forth in row 11 is calculated based upon 96,914,418 shares of the common stock of the Issuer outstanding as of October 29, 2025, as reported on the cover of the Issuer's Quarterly Report on Form 10-Q for the period ended September 30, 2025 filed with the Securities and Exchange Commission on November 6, 2025 (the "Form 10-Q").


    SCHEDULE 13G

    CUSIP No.
    12529R107


    1Names of Reporting Persons

    Soleus Private Equity GP III, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    6,072,822.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    6,072,822.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,072,822.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.9 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  (1) The shares reported in the table above are held directly by Soleus PE. Soleus PE GP is the sole general partner of Soleus PE, Soleus PE GP III, LLC is the sole manager of Soleus PE GP, SCM is the investment manager for Soleus PE and for Master Fund, and Soleus GP, LLC is the sole general partner of SCM. Guy Levy is the sole managing member of each of Soleus PE GP III, LLC and of Soleus GP, LLC. Each of Mr. Levy, Soleus PE GP III, LLC, Soleus PE GP, SCM and Soleus GP, LLC disclaims beneficial ownership of these shares held by Soleus PE other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose. (2) The number of shares reported in the table above includes warrants to purchase up to 5,822,829 shares of the common stock of the Issuer. (3) The percentage set forth in row 11 is calculated based upon 96,914,418 shares of the common stock of the Issuer outstanding as of October 29, 2025, as set forth on the cover of the Form 10-Q.


    SCHEDULE 13G

    CUSIP No.
    12529R107


    1Names of Reporting Persons

    Soleus PE GP III, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    6,072,822.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    6,072,822.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,072,822.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.9 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  (1) The shares reported in the table above are held directly by Soleus PE. Soleus PE GP is the sole general partner of Soleus PE, Soleus PE GP III, LLC is the sole manager of Soleus PE GP, SCM is the investment manager for Soleus PE and for Master Fund, and Soleus GP, LLC is the sole general partner of SCM. Guy Levy is the sole managing member of each of Soleus PE GP III, LLC and of Soleus GP, LLC. Each of Mr. Levy, Soleus PE GP III, LLC, Soleus PE GP, SCM and Soleus GP, LLC disclaims beneficial ownership of these shares held by Soleus PE other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose. (2) The number of shares reported in the table above includes warrants to purchase up to 5,822,829 shares of the common stock of the Issuer. (3) The percentage set forth in row 11 is calculated based upon 96,914,418 shares of the common stock of the Issuer outstanding as of October 29, 2025, as set forth on the cover of the Form 10-Q.


    SCHEDULE 13G

    CUSIP No.
    12529R107


    1Names of Reporting Persons

    Soleus Capital Master Fund, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    10,361,860.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    10,361,860.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    10,361,860.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    FI

    Comment for Type of Reporting Person:  (1) The shares reported in the table above are held directly by Master Fund. Soleus Capital, LLC is the sole general partner of Master Fund, Soleus Capital Group, LLC ("SCG") is the sole managing member of Soleus Capital, LLC, SCM is the investment manager for Soleus PE and for Master Fund, and Soleus GP, LLC is the sole general partner of SCM. Guy Levy is the sole managing member of each of SCG and of Soleus GP, LLC. Each of SCG, Soleus Capital, LLC, SCM, Soleus GP, LLC and Mr. Levy disclaims beneficial ownership of these shares held by Master Fund other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose. (2) The number of shares reported in the table above includes warrants to purchase up to 6,807,911 shares of the common stock of the Issuer, and reflects the maximum number of shares of common stock that may be held by the Reporting Person as a result of the beneficial ownership limitations set forth in such warrants. (3) The percentage set forth in row 11 is calculated based upon 96,914,418 shares of the common stock of the Issuer outstanding as of October 29, 2025, as set forth on the cover of the Form 10-Q.


    SCHEDULE 13G

    CUSIP No.
    12529R107


    1Names of Reporting Persons

    Soleus Capital, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    10,361,860.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    10,361,860.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    10,361,860.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  (1) The shares reported in the table above are held directly by Master Fund. Soleus Capital, LLC is the sole general partner of Master Fund, SCG is the sole managing member of Soleus Capital, LLC, SCM is the investment manager for Soleus PE and for Master Fund, and Soleus GP, LLC is the sole general partner of SCM. Guy Levy is the sole managing member of each of SCG and of Soleus GP, LLC. Each of SCG, Soleus Capital, LLC, SCM, Soleus GP, LLC and Mr. Levy disclaims beneficial ownership of these shares held by Master Fund other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose. (2) The number of shares reported in the table above includes warrants to purchase up to 6,807,911 shares of the common stock of the Issuer, and reflects the maximum number of shares of common stock that may be held by the Reporting Person as a result of the beneficial ownership limitations set forth in such warrants. (3) The percentage set forth in row 11 is calculated based upon 96,914,418 shares of the common stock of the Issuer outstanding as of October 29, 2025, as set forth on the cover of the Form 10-Q.


    SCHEDULE 13G

    CUSIP No.
    12529R107


    1Names of Reporting Persons

    Soleus Capital Group, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    10,361,860.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    10,361,860.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    10,361,860.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  (1) The shares reported in the table above are held directly by Master Fund. Soleus Capital, LLC is the sole general partner of Master Fund, SCG is the sole managing member of Soleus Capital, LLC, SCM is the investment manager for Soleus PE and for Master Fund, and Soleus GP, LLC is the sole general partner of SCM. Guy Levy is the sole managing member of each of SCG and of Soleus GP, LLC. Each of SCG, Soleus Capital, LLC, SCM, Soleus GP, LLC and Mr. Levy disclaims beneficial ownership of these shares held by Master Fund other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose. (2) The number of shares reported in the table above includes warrants to purchase up to 6,807,911 shares of the common stock of the Issuer, and reflects the maximum number of shares of common stock that may be held by the Reporting Person as a result of the beneficial ownership limitations set forth in such warrants. (3) The percentage set forth in row 11 is calculated based upon 96,914,418 shares of the common stock of the Issuer outstanding as of October 29, 2025, as set forth on the cover of the Form 10-Q.


    SCHEDULE 13G

    CUSIP No.
    12529R107


    1Names of Reporting Persons

    Soleus Capital Management, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    10,334,114.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    10,334,114.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    10,334,114.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  (1) The shares reported in the table above are held directly by Soleus PE and by Master Fund. Soleus PE GP is the sole general partner of Soleus PE, Soleus PE GP III, LLC is the sole manager of Soleus PE GP, SCM is the investment manager for Soleus PE, and Soleus GP, LLC is the sole general partner of SCM. Soleus Capital, LLC is the sole general partner of Master Fund, SCG is the sole managing member of Soleus Capital, LLC, SCM is the investment manager for Master Fund, and Soleus GP, LLC is the sole general partner of SCM. Guy Levy is the sole managing member of each of Soleus PE GP III, LLC, SCG and Soleus GP, LLC. Each of Soleus PE GP, Soleus PE GP III, LLC, Soleus Capital, LLC, SCG, SCM, Soleus GP, LLC and Mr. Levy disclaims beneficial ownership of these shares held directly by Soleus PE and Master Fund other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose. (2) The number of shares reported in the table above includes warrants to purchase up to 6,530,172 shares of the common stock of the Issuer, and reflects the maximum number of shares of common stock that may be held by the Reporting Person as a result of the beneficial ownership limitations set forth in such warrants. (3) The percentage set forth in row 11 is calculated based upon 96,914,418 shares of the common stock of the Issuer outstanding as of October 29, 2025, as set forth on the cover of the Form 10-Q.


    SCHEDULE 13G

    CUSIP No.
    12529R107


    1Names of Reporting Persons

    Soleus GP, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    10,334,114.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    10,334,114.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    10,334,114.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  (1) The shares reported in the table above are held directly by Soleus PE and by Master Fund. Soleus PE GP is the sole general partner of Soleus PE, Soleus PE GP III, LLC is the sole manager of Soleus PE GP, SSCM is the investment manager for Soleus PE, and Soleus GP, LLC is the sole general partner of SCM. Soleus Capital, LLC is the sole general partner of Master Fund, SCG is the sole managing member of Soleus Capital, LLC, SCM is the investment manager for Master Fund, and Soleus GP, LLC is the sole general partner of SCM. Guy Levy is the sole managing member of each of Soleus PE GP III, LLC, SCG and Soleus GP, LLC. Each of Soleus PE GP, Soleus PE GP III, LLC, Soleus Capital, LLC, SCG, SCM, Soleus GP, LLC and Mr. Levy disclaims beneficial ownership of these shares held directly by Soleus PE and Master Fund other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose. (2) The number of shares reported in the table above includes warrants to purchase up to 6,530,172 shares of the common stock of the Issuer, and reflects the maximum number of shares of common stock that may be held by the Reporting Person as a result of the beneficial ownership limitations set forth in such warrants. (3) The percentage set forth in row 11 is calculated based upon 96,914,418 shares of the common stock of the Issuer outstanding as of October 29, 2025, as set forth on the cover of the Form 10-Q.


    SCHEDULE 13G

    CUSIP No.
    12529R107


    1Names of Reporting Persons

    Guy Levy
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    10,334,114.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    10,334,114.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    10,334,114.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  (1) The shares reported in the table above are held directly by Soleus PE and by Master Fund. Soleus PE GP is the sole general partner of Soleus PE, Soleus PE GP III, LLC is the sole manager of Soleus PE GP, SCM is the investment manager for Soleus PE, and Soleus GP, LLC is the sole general partner of SCM. Soleus Capital, LLC is the sole general partner of Master Fund, SCG is the sole managing member of Soleus Capital, LLC, SCM is the investment manager for Master Fund, and Soleus GP, LLC is the sole general partner of SCM. Guy Levy is the sole managing member of each of Soleus PE GP III, LLC, SCG and Soleus GP, LLC. Each of Soleus PE GP, Soleus PE GP III, LLC, Soleus Capital, LLC, SCG, SCM, Soleus GP, LLC and Mr. Levy disclaims beneficial ownership of these shares held directly by Soleus PE and Master Fund other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose. (2) The number of shares reported in the table above includes warrants to purchase up to 6,530,172 shares of the common stock of the Issuer, and reflects the maximum number of shares of common stock that may be held by the Reporting Person as a result of the beneficial ownership limitations set forth in such warrants. (3) The percentage set forth in row 11 is calculated based upon 96,914,418 shares of the common stock of the Issuer outstanding as of October 29, 2025, as set forth on the cover of the Form 10-Q.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    C4 Therapeutics, Inc
    (b)Address of issuer's principal executive offices:

    490 Arsenal Way, Suite 120, Watertown, MA 02472
    Item 2. 
    (a)Name of person filing:

    Soleus Private Equity GP III, LLC Soleus Private Equity Fund III, L.P. Soleus PE GP III, LLC Soleus Capital Master Fund, L.P. Soleus Capital, LLC Soleus Capital Group, LLC Soleus Capital Management, L.P. Soleus GP, LLC Guy Levy
    (b)Address or principal business office or, if none, residence:

    Soleus Private Equity GP III, LLC 100 Field Point Road, Suite 200 Greenwich, CT 06830 Soleus Private Equity Fund III, L.P. 100 Field Point Road, Suite 200 Greenwich, CT 06830 Soleus PE GP III, LLC 100 Field Point Road, Suite 200 Greenwich, CT 06830 Soleus Capital Master Fund, L.P. 100 Field Point Road, Suite 200 Greenwich, CT 06830 Soleus Capital, LLC 100 Field Point Road, Suite 200 Greenwich, CT 06830 Soleus Capital Group, LLC 100 Field Point Road, Suite 200 Greenwich, CT 06830 Soleus Capital Management, L.P. 100 Field Point Road, Suite 200 Greenwich, CT 06830 Soleus GP, LLC 100 Field Point Road, Suite 200 Greenwich, CT 06830 Guy Levy c/o Soleus Capital Management, L.P. 100 Field Point Road, Suite 200 Greenwich, CT 06830
    (c)Citizenship:

    Soleus Private Equity GP III, LLC - Delaware Soleus Private Equity Fund III, L.P. - Delaware Soleus PE GP III, LLC - Delaware Soleus Capital Master Fund, L.P. - Cayman Islands Soleus Capital, LLC - Delaware Soleus Capital Group, LLC - Delaware Soleus Capital Management, L.P. - Delaware Soleus GP, LLC - Delaware Guy Levy - United States
    (d)Title of class of securities:

    Common Stock, par value $0.0001 per share
    (e)CUSIP No.:

    12529R107
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information in rows 5 through 9 and 11 on the cover pages to this Schedule 13G, including the footnotes thereto, is hereby incorporated by reference. Soleus Private Equity GP III, LLC - 6,072,822 Soleus Private Equity Fund III, L.P. - 6,072,822 Soleus PE GP III, LLC - 6,072,822 Soleus Capital Master Fund, L.P. - 10,361,860 Soleus Capital, LLC - 10,361,860 Soleus Capital Group, LLC - 10,361,860 Soleus Capital Management, L.P. - 10,334,114 Soleus GP, LLC - 10,334,114 Guy Levy - 10,334,114
    (b)Percent of class:

    Soleus Private Equity GP III, LLC - 5.9% Soleus Private Equity Fund III, L.P. - 5.9% Soleus PE GP III, LLC - 5.9% Soleus Capital Master Fund, L.P. - 9.99% Soleus Capital, LLC - 9.99% Soleus Capital Group, LLC - 9.99% Soleus Capital Management, L.P. - 9.99% Soleus GP, LLC - 9.99% Guy Levy - 9.99%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    Soleus Private Equity GP III, LLC - 6,072,822 Soleus Private Equity Fund III, L.P. - 6,072,822 Soleus PE GP III, LLC - 6,072,822 Soleus Capital Master Fund, L.P. - 10,361,860 Soleus Capital, LLC - 10,361,860 Soleus Capital Group, LLC - 10,361,860 Soleus Capital Management, L.P. - 10,334,114 Soleus GP, LLC - 10,334,114 Guy Levy - 10,334,114

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    Soleus Private Equity GP III, LLC - 6,072,822 Soleus Private Equity Fund III, L.P. - 6,072,822 Soleus PE GP III, LLC - 6,072,822 Soleus Capital Master Fund, L.P. - 10,361,860 Soleus Capital, LLC - 10,361,860 Soleus Capital Group, LLC - 10,361,860 Soleus Capital Management, L.P. - 10,334,114 Soleus GP, LLC - 10,334,114 Guy Levy - 10,334,114

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Soleus Private Equity Fund III, L.P.
     
    Signature:/s/ Guy Levy
    Name/Title:Guy Levy/Managing Member
    Date:02/12/2026
     
    Soleus Private Equity GP III, LLC
     
    Signature:/s/ Guy Levy
    Name/Title:Guy Levy/Managing Member
    Date:02/12/2026
     
    Soleus PE GP III, LLC
     
    Signature:/s/ Guy Levy
    Name/Title:Guy Levy/Managing Member
    Date:02/12/2026
     
    Soleus Capital Master Fund, L.P.
     
    Signature:/s/ Guy Levy
    Name/Title:Guy Levy/Managing Member
    Date:02/12/2026
     
    Soleus Capital, LLC
     
    Signature:/s/ Guy Levy
    Name/Title:Guy Levy/Managing Member
    Date:02/12/2026
     
    Soleus Capital Group, LLC
     
    Signature:/s/ Guy Levy
    Name/Title:Guy Levy/Managing Member
    Date:02/12/2026
     
    Soleus Capital Management, L.P.
     
    Signature:/s/ Guy Levy
    Name/Title:Guy Levy/Managing Member
    Date:02/12/2026
     
    Soleus GP, LLC
     
    Signature:/s/ Guy Levy
    Name/Title:Guy Levy/Managing Member
    Date:02/12/2026
     
    Guy Levy
     
    Signature:/s/ Guy Levy
    Name/Title:Guy Levy
    Date:02/12/2026
    Get the next $CCCC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CCCC

    DatePrice TargetRatingAnalyst
    12/2/2025Buy
    TD Cowen
    9/17/2025$8.00Overweight
    Barclays
    9/15/2025$6.00Equal-Weight → Overweight
    Stephens
    9/4/2025$8.00Buy
    Guggenheim
    12/19/2024$8.00 → $12.00Equal Weight → Overweight
    Wells Fargo
    11/18/2024$4.00Equal-Weight
    Stephens
    1/29/2024$6.00Underweight → Neutral
    JP Morgan
    12/13/2023$2.00 → $12.00Hold → Buy
    Stifel
    More analyst ratings

    $CCCC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Reyno Leonard sold $22,200 worth of shares (10,000 units at $2.22), decreasing direct ownership by 6% to 156,382 units (SEC Form 4)

    4 - C4 Therapeutics, Inc. (0001662579) (Issuer)

    1/16/26 4:27:58 PM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Anderson Kenneth Carl was granted 5,958 shares, increasing direct ownership by 4% to 146,532 units (SEC Form 4)

    4 - C4 Therapeutics, Inc. (0001662579) (Issuer)

    1/5/26 4:10:46 PM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Grogan Donna Roy was granted 7,513 shares, increasing direct ownership by 13% to 66,142 units (SEC Form 4)

    4 - C4 Therapeutics, Inc. (0001662579) (Issuer)

    1/5/26 4:10:26 PM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CCCC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen initiated coverage on C4 Therapeutics

    TD Cowen initiated coverage of C4 Therapeutics with a rating of Buy

    12/2/25 8:23:26 AM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Barclays initiated coverage on C4 Therapeutics with a new price target

    Barclays initiated coverage of C4 Therapeutics with a rating of Overweight and set a new price target of $8.00

    9/17/25 8:06:28 AM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    C4 Therapeutics upgraded by Stephens with a new price target

    Stephens upgraded C4 Therapeutics from Equal-Weight to Overweight and set a new price target of $6.00

    9/15/25 8:00:09 AM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CCCC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    WATERTOWN, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase 162,880 shares of the Company's common stock to one new employee (the "Inducement Grant"), with the grant made on February 9, 2026 (the "Grant Date"). The Inducement Grant was granted as a material inducement to this individual entering into employment with C4T in accordance with Nasdaq

    2/9/26 4:01:00 PM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

    WATERTOWN, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that C4T management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 taking place from February 11 – 12, 2026 in New York, NY. Fireside Chat Details:Date: Wednesday, February 11, 2026 Time: 11:30 AM ET A live webcast will be available on the Investors section of the company's website at www.c4therapeutics.com. An archived replay of the webcast will be available for approximately 90 days following the event. About C4 Therapeutic

    2/4/26 7:00:00 AM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    WATERTOWN, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase 85,480 shares of the Company's common stock to one new employee (the "Inducement Grant"), with the grant made on January 26, 2026 (the "Grant Date"). The Inducement Grant was granted as a material inducement to this individual entering into employment with C4T in accordance with Nasdaq

    1/26/26 4:01:00 PM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CCCC
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by C4 Therapeutics Inc.

    SCHEDULE 13G/A - C4 Therapeutics, Inc. (0001662579) (Subject)

    2/12/26 5:02:01 PM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by C4 Therapeutics Inc.

    SCHEDULE 13G/A - C4 Therapeutics, Inc. (0001662579) (Subject)

    2/11/26 12:58:54 PM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    C4 Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - C4 Therapeutics, Inc. (0001662579) (Filer)

    1/14/26 7:12:35 AM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CCCC
    Leadership Updates

    Live Leadership Updates

    View All

    C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting

    Cemsidomide in Combination With Dexamethasone Achieved a 50% Overall Response Rate (ORR) at the Highest Dose Level (100 µg) and a 40% ORR at the 75 µg Dose Level in a Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma Patient Population Responses Across Dose Levels With Median Duration of Response of 9.3 Months as of the Data Cut-off Date; Median Duration of Response Not Yet Reached at Two Highest Doses No Discontinuations Related to Cemsidomide and Few Dose Reductions Support a Safety Profile That May Be Ideal for Combination Regimens C4T to Pursue Differentiated Development Strategy With Two Distinct Opportunities for Accelerated Approval in Second Line and Later C4T to Host Webc

    9/20/25 11:00:20 AM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting

    WATERTOWN, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that data from its Phase 1 dose escalation clinical trial of cemsidomide in multiple myeloma (MM) will be shared in an oral presentation at the International Myeloma Society (IMS) Annual Meeting on September 20, 2025 at 11:10 am ET in Toronto, Canada. IMS Annual Meeting 2025 Oral PresentationTitle: Updated Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDAC® Degrader, with Dexamethasone in Patients with Relapsed/Refractory Multiple MyelomaPresen

    9/3/25 7:00:00 AM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

    Planning Activities Are Ongoing for Next Phase of Cemsidomide Clinical Development in Multiple Myeloma and Non-Hodgkin's Lymphoma; Trials Expected to Initiate in Early 2026 CFT1946 Phase 1/2 Trial Continues to Progress Across Multiple Cohorts; Data in Melanoma and Colorectal Cancer Expected in Second Half of 2025 Cash, Cash Equivalents and Marketable Securities of $267.3 million as of December 31, 2024; Expected to Provide Runway into 2027 WATERTOWN, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today reported financial results for the year ended

    2/27/25 7:00:00 AM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CCCC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by C4 Therapeutics Inc.

    SC 13G/A - C4 Therapeutics, Inc. (0001662579) (Subject)

    11/14/24 7:53:04 PM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by C4 Therapeutics Inc.

    SC 13G - C4 Therapeutics, Inc. (0001662579) (Subject)

    11/14/24 6:43:36 PM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by C4 Therapeutics Inc.

    SC 13G/A - C4 Therapeutics, Inc. (0001662579) (Subject)

    11/14/24 4:05:17 PM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CCCC
    Financials

    Live finance-specific insights

    View All

    C4 Therapeutics Presents Clinical Data from Cohort A of the Ongoing Phase 1/2 Clinical Trial of CFT7455, a Novel IKZF1/3 Degrader

    – Single Agent CFT7455 Induces Deep and Durable Degradation of IKZF1/3 and Meaningful Decreases in Serum Free Light Chain at Doses Lower than Expected Based on Pre-clinical Studies – – CFT7455 Exhibits Differentiated Pharmacokinetics (PK) and Potency Relative to Approved and Investigational IKZF1/3 Degraders – – On-Target Dose Limiting Toxicity Observed; Modeling Suggests Differentiated Activity and PK Profile Provides Pathway to Increase Therapeutic Index with Alternative Dosing Schedule – – Company to Host Conference Call and Webcast Today at 2 pm ET – WATERTOWN, Mass., April 08, 2022 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical co

    4/8/22 1:00:00 PM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    C4 Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2022

    - Clinical Data from Cohort A of the Ongoing Phase 1/2 Trial of CFT7455, a Novel IKZF1/3 Degrader, Accepted as Late-Breaker Poster Presentation – - New Pre-clinical Data from CFT7455; CFT8634, a BRD9 Degrader; and CFT1946, a BRAF V600X Degrader, Accepted as Oral Presentations – - Conference Call and Webcast Scheduled for April 8, 2022, at 2 PM ET– WATERTOWN, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced that the Company will pr

    3/8/22 4:30:00 PM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care